Meeting
2019 ASCO Annual Meeting
Oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG): Experience with retreatment of survivors from the phase I trial.
Authors
Annick Desjardins
Duke University Medical Center, Durham, NC
Annick Desjardins , Matthias Gromeier , James Emmett Herndon II, Dina Randazzo , Stevie Threatt , Eric S. Lipp , Elizabeth S. Miller , Jennifer Jackman , Dani P. Bolognesi , Allan H. Friedman , Henry S. Friedman , Frances McSherry , Katherine B. Peters , Margaret O Johnson , John H. Sampson , David M. Ashley , Darell D. Bigner
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT01491893
Citation
J Clin Oncol 37, 2019 (suppl; abstr 2060)
DOI
10.1200/JCO.2019.37.15_suppl.2060
Abstract #
2060
Poster Bd #
249
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Patient survival on the dose escalation phase of the Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG) clinical trial compared to historical controls.
First Author: Annick Desjardins
Poster
2016 ASCO Annual Meeting
Phase 1, multicenter, open-label, dose-escalation, study of marizomib (MRZ) and bevacizumab (BEV) in WHO grade IV malignant glioma (G4 MG).
First Author: Daniela Annenelie Bota
Poster
2020 ASCO Virtual Scientific Program
APOLLO: A phase I study of adaptive memory natural killer (NK) cells in recurrent ovarian cancer.
First Author: Melissa Ann Geller
Poster
2020 ASCO Virtual Scientific Program
Phase I trial of D2C7 immunotoxin (D2C7-IT) administered intratumorally via convection-enhanced delivery (CED) for recurrent malignant glioma (MG).
First Author: Annick Desjardins